|Grant Number:||5R01CA141298-03 Interpret this number|
|Primary Investigator:||Stampfer, Meir|
|Organization:||Brigham And Women'S Hospital|
|Project Title:||Growth Factors and Lethal Prostate Cancer Signature|
DESCRIPTION (provided by applicant): A central issue in prostate cancer (PCa) is to recognize potentially lethal cancer at diagnosis, and to identify the causes and underlying mechanisms that distinguish lethal from indolent disease. Using a case-only design, we will develop a molecular signature for potentially lethal PCa by comparing the RNA expression profiles of tumor tissue from subsequently lethal PCa cases to tumor tissue from men without known lethal disease. Collaborating with researchers at the Broad Institute of Harvard University/MIT, we propose to apply a novel but proven high-throughput profiling technology to assess RNA expression in archival tumor tissue using a 24,000 gene platform. Our previous work provided converging evidence of a key role of the insulin-like growth factor (IGF) system in PCa risk and progression. We have already assembled an extensive prospective clinical and serological database on PCa with up to 26 years of follow-up. Germline polymorphisms and plasma levels of the IGF axis have been assayed in many cases who provided a prediagnostic blood sample. We now propose to extend this work with additional IGF/insulin components, including germline variations and tumor expression, in relation to PCa progression and mortality. Using a case-only design, we will assess circulating biomarkers and tagging germline polymorphisms in the IGF/insulin axis, comparing lethal cases to men without known lethal disease. We will also assess alterations of IGF/insulin signaling in PCa tissue (RNA and protein expression) in relation to fatal PCa, and will integrate plasma and genetic biomarkers with tumor tissue data to illuminate gene pathways that are dysregulated. Based on intriguing preliminary data, we will characterize tumor samples for presence of the common gene translocation, the TMPRSS2:ERG fusion, and address whether fusion positive tumors are more likely to progress when exposed to high levels of IGF/insulin signaling. The research will be conducted in the Physicians' Health Study (PHS) and Health Professionals Follow-up Study (HPFS) cohorts among incident PCa cases diagnosed from 1982-2008. We have assembled a PCa tumor repository of 1,600 cases (178 fatal) for tissue marker assays and are constructing high-density tissue microarrays for quantitative immunohistochemistry and FISH assays. We will have levels of circulating biomarkers measured in plasma (N=1,881) and SNPs assayed on extracted DNA (N=2,281). All men with PCa are followed intensively for information on treatment, PSA rise, metastases and cause of death with complete follow-up through 2012. The RNA expression data will greatly enhance our understanding of the influence of the IGF/insulin dependent and independent pathways on development of lethal PCa, which will aid in designing targeted therapy and prevention strategies. Most studies of PCa progression are based on elevations of PSA levels. A major strength of our proposal is that we use the most clinically relevant endpoint, lethal PCa. From the molecular signature of lethal PCa, we can identify a small number of highly predictive markers that could be ultimately assessed in biopsy samples. Thus, the findings can be translated to clinical practice, enabling clinicians to identify with confidence which tumors require aggressive therapy. Use of this rich resource of existing data and infrastructure permits a highly cost-efficient study, and the cross-disciplinary team of collaborators with a longstanding record of working together will ensure success of this project. PUBLIC HEALTH RELEVANCE: Prostate cancer is among the most common cancers in men, and a major cause of cancer death. A central problem is that with PSA screening, many men are diagnosed with a cancer that would not cause them harm, and they undergo therapy unnecessarily. We propose to use an exciting innovative technology to identify a molecular tumor signature to distinguish prostate cancers that are indolent, and can safely be left untreated, from those that are potentially lethal and require aggressive therapy. We also plan to extend our work to identify the causes of lethal prostate cancer as they relate to the growth factor pathway.
Replication of a genetic variant for prostate cancer-specific mortality.
Authors: Penney KL, Shui IM, Feng Z, Sesso HD, Stampfer MJ, Stanford JL
Source: Prostate Cancer Prostatic Dis, 2015 May 5;null, p. null.
EPub date: 2015 May 5.
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer.
Authors: Graff RE, Pettersson A, Lis RT, DuPre N, Jordahl KM, Nuttall E, Rider JR, Fiorentino M, Sesso HD, Kenfield SA, Loda M, Giovannucci EL, Rosner B, Nguyen PL, Sweeney CJ, Mucci LA, Transdisciplinary Prostate Cancer Partnership ToPCaP
Source: Prostate, 2015 Jun;75(9), p. 897-906.
EPub date: 2015 Mar 1.
The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era.
Authors: Jahn JL, Giovannucci EL, Stampfer MJ
Source: Int J Cancer, 2014 Dec 29;null, p. null.
EPub date: 2014 Dec 29.
Selenium supplementation and prostate cancer mortality.
Authors: Kenfield SA, Van Blarigan EL, DuPre N, Stampfer MJ, L Giovannucci E, Chan JM
Source: J Natl Cancer Inst, 2015 Jan;107(1), p. 360.
EPub date: 2014 Dec 12.
Circadian clock genes and risk of fatal prostate cancer.
Authors: Markt SC, Valdimarsdottir UA, Shui IM, Sigurdardottir LG, Rider JR, Tamimi RM, Batista JL, Haneuse S, Flynn-Evans E, Lockley SW, Czeisler CA, Stampfer MJ, Launer L, Harris T, Smith AV, Gudnason V, Lindstrom S, Kraft P, Mucci LA
Source: Cancer Causes Control, 2015 Jan;26(1), p. 25-33.
EPub date: 2014 Nov 12.
Association of prostate cancer risk variants with gene expression in normal and tumor tissue.
Authors: Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ
Source: Cancer Epidemiol Biomarkers Prev, 2015 Jan;24(1), p. 255-60.
EPub date: 2014 Nov 4.
Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer.
Authors: Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL
Source: Int J Cancer, 2015 May 15;136(10), p. 2418-26.
EPub date: 2014 Nov 10.
Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies.
Authors: Crowe FL, Appleby PN, Travis RC, Barnett M, Brasky TM, Bueno-de-Mesquita HB, Chajes V, Chavarro JE, Chirlaque MD, English DR, Gibson RA, Giles GG, Goodman GE, Henning SM, Kaaks R, King IB, Kolonel LN, Kristal AR, Neuhouser ML, Park SY, Severi G, Siddiq A, Stampfer MJ, Stattin P, Tangen CM, Tj°nneland A, Trichopoulos D, Tumino R, Wilkens LR, Key TJ, Allen NE, Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
Source: J Natl Cancer Inst, 2014 Sep;106(9), p. null.
EPub date: 2014 Sep 10.
Vasectomy and risk of aggressive prostate cancer: a 24-year follow-up study.
Authors: Siddiqui MM, Wilson KM, Epstein MM, Rider JR, Martin NE, Stampfer MJ, Giovannucci EL, Mucci LA
Source: J Clin Oncol, 2014 Sep 20;32(27), p. 3033-8.
Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer.
Authors: Yoo S, Pettersson A, Jordahl KM, Lis RT, Lindstrom S, Meisner A, Nuttall EJ, Stack EC, Stampfer MJ, Kraft P, Brown M, Loda M, Giovannucci EL, Kantoff PW, Mucci LA
Source: Cancer Epidemiol Biomarkers Prev, 2014 Oct;23(10), p. 2027-31.
EPub date: 2014 Jun 12.
Genetic variation across C-reactive protein and risk of prostate cancer.
Authors: Markt SC, Rider JR, Penney KL, Schumacher FR, Epstein MM, Fall K, Sesso HD, Stampfer MJ, Mucci LA
Source: Prostate, 2014 Jul;74(10), p. 1034-42.
EPub date: 2014 May 20.
Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.
Authors: Cao Y, Lindstr÷m S, Schumacher F, Stevens VL, Albanes D, Berndt S, Boeing H, Bueno-de-Mesquita HB, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Le Marchand L, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J
Source: J Natl Cancer Inst, 2014 Jun;106(6), p. dju085.
Plasma antioxidants, genetic variation in SOD2, CAT, GPX1, GPX4, and prostate cancer survival.
Authors: Van Blarigan EL, Ma J, Kenfield SA, Stampfer MJ, Sesso HD, Giovannucci EL, Witte JS, Erdman JW Jr, Chan JM, Penney KL
Source: Cancer Epidemiol Biomarkers Prev, 2014 Jun;23(6), p. 1037-46.
EPub date: 2014 Apr 7.
SPINK1 protein expression and prostate cancer progression.
Authors: Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, Judson GL, Lis R, Bailey D, Fiore C, Nuttall E, Martin NE, Stack E, Penney KL, Rider JR, Sinnott J, Sweeney C, Sesso HD, Fall K, Giovannucci E, Kantoff P, Stampfer M, Loda M, Mucci LA
Source: Clin Cancer Res, 2014 Sep 15;20(18), p. 4904-11.
EPub date: 2014 Mar 31.
Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study.
Authors: Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA
Source: Cancer Causes Control, 2014 May;25(5), p. 625-32.
EPub date: 2014 Mar 25.
Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study.
Authors: Alemozaffar M, Sanda M, Yecies D, Mucci LA, Stampfer MJ, Kenfield SA
Source: Eur Urol, 2015 Mar;67(3), p. 432-8.
EPub date: 2014 Feb 11.
Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era.
Authors: Zu K, Mucci L, Rosner BA, Clinton SK, Loda M, Stampfer MJ, Giovannucci E
Source: J Natl Cancer Inst, 2014 Feb;106(2), p. djt430.
EPub date: 2014 Jan 24.
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG.
Authors: Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA
Source: J Natl Cancer Inst, 2013 Dec 18;105(24), p. 1881-90.
EPub date: 2013 Nov 30.
Mounting evidence for prediagnostic use of statins in reducing risk of lethal prostate cancer.
Authors: Mucci LA, Stampfer MJ
Source: J Clin Oncol, 2014 Jan 1;32(1), p. 1-2.
EPub date: 2013 Nov 25.
Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.
Authors: Kasperzyk JL, Finn SP, Flavin R, Fiorentino M, Lis R, Hendrickson WK, Clinton SK, Sesso HD, Giovannucci EL, Stampfer MJ, Loda M, Mucci LA
Source: Cancer Epidemiol Biomarkers Prev, 2013 Dec;22(12), p. 2354-63.
EPub date: 2013 Oct 15.
Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer.
Authors: Chavarro JE, Kenfield SA, Stampfer MJ, Loda M, Campos H, Sesso HD, Ma J
Source: Am J Epidemiol, 2013 Oct 15;178(8), p. 1246-55.
EPub date: 2013 Aug 28.
Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
Authors: Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn S, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci E
Source: Cancer Epidemiol Biomarkers Prev, 2013 Nov;22(11), p. 1984-93.
EPub date: 2013 Aug 27.
Mediterranean diet and prostate cancer risk and mortality in the Health Professionals Follow-up Study.
Authors: Kenfield SA, DuPre N, Richman EL, Stampfer MJ, Chan JM, Giovannucci EL
Source: Eur Urol, 2014 May;65(5), p. 887-94.
EPub date: 2013 Aug 13.
Gleason grade progression is uncommon.
Authors: Penney KL, Stampfer MJ, Jahn JL, Sinnott JA, Flavin R, Rider JR, Finn S, Giovannucci E, Sesso HD, Loda M, Mucci LA, Fiorentino M
Source: Cancer Res, 2013 Aug 15;73(16), p. 5163-8.